Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
Study sponsor: MacroGenics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-01-15Actual
Enrollment · participants82Actual
Source updated2025-06-08Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.